Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.45 |
| ▸ | MGLL | Q99685 | 3/20 | 0.45 |
| ▸ | LPL | P06858 | 3/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466370 | 0.83 | MAPT (0.34) | TSHR | |
| SCHEMBL147828 | 0.79 | CA2 (0.52) | CA2CA1ENPP2MGLLLPL | |
| SCHEMBL1330772 | 0.79 | ENPP2 (0.51) | CA2CA1ENPP2MGLLLPL | |
| SCHEMBL3271256 | 0.78 | ESR1 (0.42) | — | |
| SCHEMBL25968742 | 0.76 | CA2 (0.54) | CA2CA1ENPP2MGLLLPL | |
| SCHEMBL6610143 | 0.74 | CA1 (0.48) | CA2CA1ENPP2MGLLABL1 | |
| SCHEMBL1393204 | 0.74 | CA1 (0.59) | CA2CA1ENPP2MGLLABL1 | |
| SCHEMBL849890 | 0.74 | CA2 (0.47) | CA2CA1ENPP2MGLLLPL | |
| SCHEMBL9586800 | 0.74 | TDP1 (0.42) | TSHR | |
| SCHEMBL26464057 | 0.73 | CA2 (0.50) | CA2CA1ENPP2MGLLLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108289457-B | Process for preparing antifungal compounds | 迈科维亚医药公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-3349586-B1 | ANTIFUNGAL COMPOUND PROCESS | MYCOVIA PHARMACEUTICALS INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10836740-B2 | Antifungal compound process | Mycovia Pharmaceuticals, Inc. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10745378-B2 | Antifungal compound process | Mycovia Pharmaceuticals, Inc. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10464921-B2 | Antifungal compound process | Mycovia Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190194160-A1 | Antifungal Compound Process | Mycovia Pharmaceuticals, Inc. | 2019-06-27 | — | — | US | disclosed |
| US-20190161470-A1 | Antifungal Compound Process | MYCOVIA PHARMACEUTICALS INC (US) | 2019-05-30 | — | — | US | disclosed |
| US-10196375-B2 | Antifungal compound process | Mycovia Pharmaceuticals, Inc. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3349586-A1 | ANTIFUNGAL COMPOUND PROCESS | Mycovia Pharmaceuticals, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20170081310-A1 | ANTIFUNGAL COMPOUND PROCESS | Mycovia Pharmaceuticals, Inc. | 2017-03-23 | — | — | US | disclosed |
| WO-2017049080-A1 | ANTIFUNGAL COMPOUND PROCESS | VIAMET PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| EP-3119754-A1 | ANTIFUNGAL COMPOUND PROCESS | Viamet Pharmaceuticals, Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015143142-A1 | ANTIFUNGAL COMPOUND PROCESS | VIAMET PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745378-B2 | Antifungal compound process | ERG28, DPM1, CYP51A1 | CA2 3534/4885CA1 4082/4885ENPP2 2713/4885 |
| US-20170081310-A1 | ANTIFUNGAL COMPOUND PROCESS | ERG28, DPM1, CYP51A1 | CA2 3534/4885CA1 4082/4885ENPP2 2713/4885 |
| US-20190194160-A1 | Antifungal Compound Process | ERG28, CYP51A1, DPM1 | CA2 3644/4885CA1 4197/4885ENPP2 2589/4885 |
| US-10836740-B2 | Antifungal compound process | ERG28, CYP51A1, DPM1 | CA2 3652/4885CA1 4210/4885ENPP2 2534/4885 |
| US-20190161470-A1 | Antifungal Compound Process | ERG28, DPM1, CYP51A1 | CA2 3534/4885CA1 4082/4885ENPP2 2713/4885 |
| US-10196375-B2 | Antifungal compound process | ERG28, DPM1, CYP51A1 | CA2 3534/4885CA1 4082/4885ENPP2 2713/4885 |
| US-10464921-B2 | Antifungal compound process | ERG28, CYP51A1, DPM1 | CA2 3644/4885CA1 4197/4885ENPP2 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.